HIF1A and systemic lupus erythematosus: L‐ascorbic acid‐a (HIF‐1α inhibitor) or bosentan (an endothelin‐1 receptor antagonist) used to lessen the release of NET targeted treatment for neutrophils, revealing that the inhibition of endothelin‐1 and HIF‐1α could significantly suppress the “pre‐NETotic” step of NET formation in human SLE.64